Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Official title: An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
43
Start Date
2008-07-31
Completion Date
2014-05-28
Last Updated
2026-10-06
Healthy Volunteers
No
Conditions
Interventions
SAR302503 (TG101348)
orally administered, once a day
Locations (6)
Investigational Site Number 840103
La Jolla, California, United States
Investigational Site Number 840102
Stanford, California, United States
Investigational Site Number 840105
Boston, Massachusetts, United States
Investigational Site Number 840106
Ann Arbor, Michigan, United States
Investigational Site Number 840104
Rochester, Minnesota, United States
Investigational Site Number 840101
Houston, Texas, United States